To analyze the incidence and course of EPI, before and after a PD for a suspected pancreatic or peri-ampullary malignancy. Furthermore, the effect of pancreatic enzyme supplementation on symptoms of EPI and the correlation of symptoms and abnormal…
ID
Source
Brief title
Condition
- Exocrine pancreas conditions
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
The primary outcome parameters are the presence of EPI (FE1<200) and the
percentage of patients that is under treated for EPI, i.e. patients who should
receive treatment for EPI based on fecal elastase 1 test and patients who are
treated for EPI but still experience symptoms reflecting EPI.
Secondary outcome
Secondary outcome parameters are symptoms of EPI (according to the CTC-AE
score), the occurrence of vitamin A, D, E, and K deficiencies and a prolonged
INR, endocrine pancreatic insufficiency (HbA1c > 42 mmol/l and/or use of oral
antidiabetics or insulin), Quality-of-life (RAND-36, QLQ-C30, and QLQ-PAN26),
and the effect of pancreatic enzyme supplementation on symptoms of EPI.
Background summary
The pancreas has both an endocrine and exocrine function. Exocrine pancreatic
insufficiency (EPI) and vitamin deficiency after pancreatoduodenectomy is
described in 33-90% of cases. These data are based on personal experiences and
short-term results from retrospective studies. To date, there are no
prospective studies that describe exocrine pancreatic insufficiency on both
short-and long-term after pancreatoduodenectomy.
Study objective
To analyze the incidence and course of EPI, before and after a PD for a
suspected pancreatic or peri-ampullary malignancy. Furthermore, the effect of
pancreatic enzyme supplementation on symptoms of EPI and the correlation of
symptoms and abnormal fecal elastase 1 test will be evaluated. In addition, the
prevalence of fat-soluble vitamin deficiencies and osteoporosis will be
evaluated. Finally, the endocrine function and quality-of-life will be
analysed.
Study design
In this prospective multicenter observational cohort study, the presence of EPI
will be evaluated in two groups; the first group (cohort A) will be followed
during the first 18 months after surgery, to evaluate short-term EPI. The
second cohort (group B) will be followed for the same period, and consists of
patients who have already survived at least 2 years after surgery, to evaluate
the long-term EPI course.
Study burden and risks
A potential benefit of participation is early diagnosis and adequate treatment
of (subclinical) EPI. Even without personal benefit for participating patients,
this study is of great importance to the treatment of EPI and the related
benefits in nutrional status and quality of life.
All study related investigations will take place during routine follow-up
moments (including the inclusion visit there will be 5 appointments in group A
and 4 in group B). Therefore, patients will not suffer the burden of additional
hospital visits. Each visit will include a short questionnaire (5-10 minutes)
and the examination of a stool sample, which patients can obtain at the privacy
of their own home. We acknowledge a small burden, but consider these tests
without risk. In addition blood samples will be drawn to assess vitamin A, D, E
and K status and blood glucose levels (total 14mL blood). This may be perceived
as a small burden, but has negligible risks.
Heidelberglaan 100
Utrecht 3584CX
NL
Heidelberglaan 100
Utrecht 3584CX
NL
Listed location countries
Age
Inclusion criteria
Group A
* Patients who will undergo a pancreatoduodenectomy for a suspected pancreatic or peri-ampullary malignancy ;Group B
* Patients who underwent pancreatoduodenectomy for suspected pancreatic or peri-ampullary malignancy at least two years previously
Exclusion criteria
Patients younger than 18 years
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
CCMO | NL41202.041.12 |